A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Obtain dose, safety, PK, and PD information about ALXN6000.
From first dose through 10 weeks after the last dose
Yes
Leonard Heffner
Principal Investigator
Emory University
United States: Food and Drug Administration
C07-003
NCT00648739
June 2008
November 2010
Name | Location |
---|---|
University of Michigan | Ann Arbor, Michigan 48109-0624 |
Duke University Medical Center | Durham, North Carolina 27710 |
Emory Winship Cancer Institute | Atlanta, Georgia 30322 |
Arizona Cancer Center at UMC North | Tucson, Arizona 85719 |
Hematology Oncology Assoc. of Northern NJ Carol G. Simon Cancer Center | Morristown, New Jersey 07962 |